HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
4.500
+0.280 (6.64%)
Oct 14, 2025, 3:19 PM EDT - Market open

HCW Biologics Statistics

Total Valuation

HCW Biologics has a market cap or net worth of $9.68 million. The enterprise value is $13.43 million.

Market Cap9.68M
Enterprise Value 13.43M

Important Dates

The next estimated earnings date is Thursday, November 13, 2025, after market close.

Earnings Date Nov 13, 2025
Ex-Dividend Date n/a

Share Statistics

HCW Biologics has 2.15 million shares outstanding. The number of shares has increased by 33.36% in one year.

Current Share Class 2.15M
Shares Outstanding 2.15M
Shares Change (YoY) +33.36%
Shares Change (QoQ) +59.38%
Owned by Insiders (%) 31.99%
Owned by Institutions (%) 4.22%
Float 1.30M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 6.21
Forward PS n/a
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 16.12
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.11

Current Ratio 0.11
Quick Ratio 0.09
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -13.87

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -30.41%
Return on Invested Capital (ROIC) -162.01%
Return on Capital Employed (ROCE) -657.05%
Revenue Per Employee $23,134
Profits Per Employee -$598,721
Employee Count36
Asset Turnover 0.03
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -77.97% in the last 52 weeks. The beta is 0.63, so HCW Biologics's price volatility has been lower than the market average.

Beta (5Y) 0.63
52-Week Price Change -77.97%
50-Day Moving Average 4.35
200-Day Moving Average 8.60
Relative Strength Index (RSI) 53.71
Average Volume (20 Days) 120,169

Short Selling Information

The latest short interest is 82,043, so 3.81% of the outstanding shares have been sold short.

Short Interest 82,043
Short Previous Month 350,555
Short % of Shares Out 3.81%
Short % of Float 6.33%
Short Ratio (days to cover) 0.07

Income Statement

In the last 12 months, HCW Biologics had revenue of $832,841 and -$21.55 million in losses. Loss per share was -$17.59.

Revenue832,841
Gross Profit 166,568
Operating Income -13.56M
Pretax Income -11.40M
Net Income -21.55M
EBITDA -12.04M
EBIT -13.56M
Loss Per Share -$17.59
Full Income Statement

Balance Sheet

The company has $2.44 million in cash and $6.79 million in debt, giving a net cash position of -$4.35 million or -$2.02 per share.

Cash & Cash Equivalents 2.44M
Total Debt 6.79M
Net Cash -4.35M
Net Cash Per Share -$2.02
Equity (Book Value) -51,972
Book Value Per Share -0.02
Working Capital -23.95M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$12.56 million and capital expenditures -$150,475, giving a free cash flow of -$12.71 million.

Operating Cash Flow -12.56M
Capital Expenditures -150,475
Free Cash Flow -12.71M
FCF Per Share -$5.91
Full Cash Flow Statement

Margins

Gross Margin 20.00%
Operating Margin -1,627.99%
Pretax Margin -1,368.83%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

HCW Biologics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -33.36%
Shareholder Yield -33.36%
Earnings Yield -237.38%
FCF Yield -139.96%

Analyst Forecast

The average price target for HCW Biologics is $35.00, which is 677.78% higher than the current price. The consensus rating is "Strong Buy".

Price Target $35.00
Price Target Difference 677.78%
Analyst Consensus Strong Buy
Analyst Count 1
Revenue Growth Forecast (5Y) 171.41%
EPS Growth Forecast (5Y) -39.70%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on April 11, 2025. It was a reverse split with a ratio of 1:40.

Last Split Date Apr 11, 2025
Split Type Reverse
Split Ratio 1:40

Scores

HCW Biologics has an Altman Z-Score of -7.23 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -7.23
Piotroski F-Score 3